IP Library Granted Patent US 8,071,301
Granted Patent B2
US 8,071,301 · App. 12/827,605 · Granted Dec 6, 2011

Method of isolating nucleic acids from a biological sample

Assignee: Gen-Probe Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,301
App. No.
12/827,605
Granted
Dec 6, 2011
Kind
B2
Abstract

Method of preparing a biological sample appropriate for use in a subsequent in vitro nucleic acid amplification reaction. The method involves a rapid, transient exposure to alkaline conditions which can be achieved by mixing an alkaline solution with a pH-buffered solution that includes a detergent and the biological sample to be tested for the presence of particular nucleic acid species using in vitro amplification. The invented method advantageously can improve detection of some target nucleic acids without substantially compromising detectability of others. The method is particularly useful for simultaneously preparing RNA and DNA templates that can be used in multiplex amplification reactions.

Claims (33)

1. A method of processing a biological sample, comprising the steps of:

(a) combining said biological sample with a pH buffer and a detergent, whereby there is created a first liquid composition having a first pH;

(b) mixing with said first liquid composition an alkaline composition, whereby there is created a second liquid composition having a second pH,

wherein said second pH is at least 0.2 pH units higher than said first pH,

wherein said second pH is lower than pH 9.5,

wherein said alkaline composition is a concentrated hydroxide solution that comprises, in aqueous solution, a strong base at 0.1 N concentration, and

wherein RNA that may be present in said biological sample is hydrolyzed if said alkaline composition is combined with said biological sample in the absence of added pH buffer; and

(c) purifying nucleic acids, comprising RNA, from said second liquid composition.

2. The method of claim 1 , wherein said pH buffer and said detergent in step (a) are each components of a buffered detergent solution, and wherein the combining step comprises combining said biological sample with an aliquot of said buffered detergent solution.

3. The method of claim 1 , wherein said strong base is selected from the group consisting of NaOH, LiOH and KOH.

4. The method of claim 1 , wherein said alkaline composition in mixing step (b) is a concentrated hydroxide solution that comprises, in aqueous solution, a strong base in the concentration range of from 0.1 N to 2.2 N.

5. The method of claim 1 , wherein purifying step (c) comprises,

(i) immobilizing nucleic acids from said second liquid composition onto a solid support by sequence-specific target capture; and

(ii) washing the solid support to remove any material not immobilized thereon.

6. The method of claim 1 , wherein purifying step (c) comprises,

(i) immobilizing nucleic acids from said second liquid composition onto a solid support by non-specific target capture that is substantially independent of base sequence; and

(ii) washing the solid support to remove any material not immobilized thereon.

7. The method of claim 1 , wherein purifying step (c) comprises capturing onto a solid support nucleic acids from said second liquid composition, and then washing the solid support to remove any material not immobilized thereon.

8. The method of claim 7 , wherein the step for capturing onto the solid support comprises immobilizing by sequence-specific target capture.

9. The method of claim 7 , wherein the step for capturing onto the solid support comprises immobilizing by non-specific target capture that is substantially independent of base sequence.

10. The method of claim 7 , wherein the nucleic acids captured onto the solid support comprise RNA and DNA.

11. The method of claim 7 , further comprising the step of performing an in vitro nucleic acid amplification reaction using the nucleic acids purified in step (c) as templates.

12. The method of claim 11 , wherein said in vitro nucleic acid amplification reaction comprises a reverse transcriptase.

13. The method of claim 7 , wherein said second pH is in the range of from pH 8.0 to pH 9.2.

14. The method of claim 1 , further comprising the step of performing an in vitro nucleic acid amplification reaction using the nucleic acids purified in step (c) as templates.

15. The method of claim 14 , wherein said in vitro nucleic acid amplification reaction comprises a reverse transcriptase.

16. The method of claim 11 , wherein said second pH is pH 9.2 or lower.

17. The method of claim 11 , wherein said second pH is in the range of pH 8.0 to pH 8.7.

18. The method of claim 11 , wherein said first pH is in the range of from pH 6.5 to pH 8.0, and wherein said second pH is in the range of from pH 8.2 to pH 9.2.

19. The method of claim 10 , further comprising the step of performing an in vitro nucleic acid amplification reaction using the nucleic acids captured onto the solid support as templates.

20. The method of claim 19 , wherein said in vitro nucleic acid amplification reaction is a multiplex in vitro nucleic acid amplification reaction that amplifies an RNA target and a DNA target.

21. The method of claim 20 , wherein said RNA target is selected from the group consisting of an HIV-1 nucleic acid sequence and an HCV nucleic acid sequence.

22. The method of claim 20 , wherein said DNA target is an HBV nucleic acid sequence.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
Continuity (5)
Continuation 12409818 · Mar 24, 2009
Continuation 11356613 · Feb 17, 2006
Provisional Application 60654199 · Feb 18, 2005
Provisional Application 60669192 · Apr 6, 2005
Related Publication 20110008847A1 · Jan 13, 2011